Cullinan Therapeutics, Inc. CGEM Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron PharmaceuticalsREGN

$37.8M+24.8%

Vor BiopharmaVOR

$307K-92.8%

Climb Bio, Inc.CLYM

$263K+69.7%

Aclaris TherapeuticsACRS

$588K+14.2%

Shattuck Labs, Inc.STTK

$874K-8.6%

Artiva Biotherapeutics, Inc.ARTV

$3.3M-6.7%

FAQ

What is Cullinan Therapeutics, Inc.'s operating lease liabilities (current)?

Cullinan Therapeutics, Inc. (CGEM) reported operating lease liabilities (current) of $666K in Q2 2026.

How has Cullinan Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?

Cullinan Therapeutics, Inc.'s operating lease liabilities (current) decreased by 52.2% year-over-year, from $1.39M to $666K.

What is the long-term trend for Cullinan Therapeutics, Inc.'s operating lease liabilities (current)?

Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 11.5% compound annual growth rate (CAGR), from $505K to $780K.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.